Latest from The Tisch Cancer Institute

Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses molecular techniques used to determine ovarian cancer following treatment with chemotherapy.
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.
Ann Marie Beddoe, MD, discusses a study implementing cervical cancer screening and highlights HPV predictors in developing countries.
Richard R.P. Warner, MD, discusses the key learnings and insights of 60 years of studying, diagnosing, and treating patients with neuroendocrine tumors and carcinoid syndrome.
William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.
John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses pacritinib in patients with myelofibrosis.
William Oh, MD, professor, Mount Sinai Hospital, discusses the results from a trial that compared second-line chemotherapy to alternative androgen receptor-targeted agents (ARTA) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Publication Bottom Border
Border Publication